View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

KPN reports on progress of € 200m share buyback

KPN reports on progress of € 200m share buyback KPN has repurchased 2,027,167 KPN ordinary shares in the period from 13 May to 17 May 2024. The shares were repurchased at an average price of € 3.45 per share for a total consideration of € 7.0m. These repurchases were made as part of the € 200m share buyback started on 1 February 2024, and are part of KPN's commitment to structurally return additional capital to its shareholders. The total number of ordinary shares repurchased up to and including 17 May 2024 is 56,029,005 for a total consideration of € 186.4m. Transaction details of the sh...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 21/05/2024

Auchan réfléchirait à une vaste restructuration de ses fonctions supportSaipem : trois nouveaux contrats remportés en Angola auprès de TotalEnergies>...

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/21/2024

Auchan is reportedly considering a major restructuring of its support functions Saipem : three new contracts awarded by TotalEnergies in Angola>...

 PRESS RELEASE

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B share...

ABGSC Capital Goods Research ... (+4)
  • ABGSC Capital Goods Research
  • Anders Idborg
  • Karl Bokvist
  • Olof Cederholm

The Capital Goods Data Miner - May 2024

Our key long ideas are: Alfa Laval, Hexagon, Metso, Sandvik, Volvo. We are cautious on: Autoliv, Nibe, Wärtsilä

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...

 PRESS RELEASE

GROUPE SEB : Descriptif du programme de rachat d’actions 2024-2025

ECULLY, France--(BUSINESS WIRE)-- Regulatory News: GROUPE SEB (Paris:SK): Etabli en application des dispositions des articles 241-1 et suivants du Règlement Général de l’Autorité des Marchés Financiers (AMF), le présent document a pour objet de décrire les objectifs et les modalités du programme de rachat d’actions qui sera soumis à l’autorisation de l’Assemblée générale mixte des actionnaires du 23 mai 2024, et dont la mise en œuvre commencera le 24 mai 2024. INTRODUCTION A la date du 30 avril 2024, le capital de la Société est composé de 55 337 770 actions (code ISIN de cotation: FR0...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Novo Nordisk : Mim8 officially in competition with Hemlibra

>Positive results for the FRONTIER2 trial evaluating Mim8 in haemophilia A - Novo reported yesterday evening the clinical results of its phase 3 trial evaluating Mim8 in haemophilia A. Some 250 patients with haemophilia A and with or without inhibitors were included in the trial. The primary endpoint was to demonstrate control of bleeding episodes. Note that this trial was structured between 2 patient cohorts: one with no initial prophylaxis treatment treatment (n=57)...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

Novo Nordisk : Mim8 officiellement en concurrence avec Hemlibra

>Résultats positifs de l’essai FRONTIER2 évaluant Mim8 en hémophilie A - Novo publiait hier soir les résultats cliniques de son essai de phase 3 évaluant Mim8 en hémophilie A. 250 patients atteints d’hémophilie A présentant ou non des inhibiteurs étaient inclus dans cet essai. Le critère primaire est de démontrer un contrôle des saignements. Il faut noter que cet essai a été structuré entre 2 cohortes de patients : l’une ayant initialement aucune prophylaxie (n=57) et...

 PRESS RELEASE

Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superi...

Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatm...

 PRESS RELEASE

KPN reports on progress of € 200m share buyback

KPN reports on progress of € 200m share buyback KPN has rKPN reports on progress of € 200m share buybackepurchased 1,995,227 KPN ordinary shares in the period from 6 May to 10 May 2024. The shares were repurchased at an average price of € 3.39 per share for a total consideration of € 6.8m. These repurchases were made as part of the € 200m share buyback started on 1 February 2024, and are part of KPN's commitment to structurally return additional capital to its shareholders. The total number of ordinary shares repurchased to date is 54,001,838 for a total consideration of € 179.4m. Transac...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 13/05/2024

Altice International : S&P dégrade le rating de B/stable à B-/négatif. Lufthansa : de retour au marché obligataire. Ceconomy raises FY 24 adj. EBIT outlook.>...

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/13/2024

Ceconomy raises FY 24 adj. EBIT outlook. Altice International: S&P cuts the rating to B-/negative from B/stable. Lufthansa: back into the bond market. >...

Michael B. Schäfer
  • Michael B. Schäfer

K+S AG : Final Q1 confirm strong prelim Q1-EBITDA on strong European s...

>Final Q1 EBITDA of € 200m confirm preliminary results vs. € 162m in Q4 23 - K+S already reported preliminary Q1 results on 30 April, beating consensus EBITDA expectations by 21% with €200m compared to €165m at consensus, also confirming €500-650m (cons € 562m) EBITDA outlook range back then. Final Q1 24 EBITDA gained 23% q/q to € 200m compared to € 162m in Q4 23, despite sequentially stable Ag volumes of 2mt and stable Ag ASP of € 336/t, i.e. positive mix at European...

Banco Bilbao Vizcaya Argentaria, S.A. - Banco Sabadell, S.A.: BBVA mak...

BBVA's somewhat risky hostile bid puts its reputation at risk, but underscores its determination to finalize this transaction.

 PRESS RELEASE

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch